Adalvo Drug Patent Portfolio

Adalvo owns 1 orange book drug protected by 4 US patents Given below is the list of Adalvo's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9579288 Tesofensine and beta blocker combination formulations 23 Jul, 2027
Active
US9597288 Transmucosal delivery devices with enhanced uptake 23 Jul, 2027
Active
US7579019 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces 22 Jan, 2020 Expired
US6159498 Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces 18 Oct, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Adalvo.

Activity Date Patent Number
Patent litigations
Expire Patent 27 Sep, 2021 US7579019 (Litigated)
Maintenance Fee Reminder Mailed 12 Apr, 2021 US7579019 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 21 Sep, 2020 US9597288
Payment of Maintenance Fee, 4th Yr, Small Entity 14 Aug, 2020 US9579288
Review Certificate Mailed 08 Feb, 2018 US7579019 (Litigated)
Review Certificate 15 Dec, 2017 US7579019 (Litigated)
Patent Issue Date Used in PTA Calculation 21 Mar, 2017 US9597288
Recordation of Patent Grant Mailed 21 Mar, 2017 US9597288
Email Notification 02 Mar, 2017 US9597288
Issue Notification Mailed 01 Mar, 2017 US9597288
Patent Issue Date Used in PTA Calculation 28 Feb, 2017 US9579288
Recordation of Patent Grant Mailed 28 Feb, 2017 US9579288
Dispatch to FDC 10 Feb, 2017 US9597288
Application Is Considered Ready for Issue 09 Feb, 2017 US9597288
Email Notification 09 Feb, 2017 US9579288


Adalvo's Drug Patent Litigations

Adalvo's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 22, 2014, against patent number US7579019. The petitioner MONOSOL RX, LLC, challenged the validity of this patent, with Arius Two, Inc. as the respondent. Click below to track the latest information on how companies are challenging Adalvo's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7579019 January, 2014 FWD Entered
(05 Aug, 2015)
Arius Two, Inc. MONOSOL RX, LLC


Adalvo's Family Patents

Adalvo drugs have patent protection in a total of 24 countries. It's US patent count contributes only to 34.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Adalvo Drug List

Given below is the complete list of Adalvo's drugs and the patents protecting them.


1. Onsolis

Onsolis is protected by 4 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9579288 Tesofensine and beta blocker combination formulations 23 Jul, 2027
(2 years from now)
Active
US9597288 Transmucosal delivery devices with enhanced uptake 23 Jul, 2027
(2 years from now)
Active
US7579019 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces 22 Jan, 2020
(4 years ago)
Expired
US6159498 Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces 18 Oct, 2016
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onsolis's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List